- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00214942
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
May 8, 2014 updated by: Cephalon
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Low Back Pain
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Low Back Pain
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Jonesboro, Arkansas, United States, 72401
- Clopton Clinic
-
-
California
-
Bakersfield, California, United States, 93311
- Vertex Clinical Research, Inc.
-
San Diego, California, United States, 92106
- San Diego Arthritis Medical
-
-
Florida
-
Clearwater, Florida, United States, 33765
- Clinical Research of W Florida
-
Jacksonville, Florida, United States, 32207
- Florida Institute of Medical R
-
Tampa, Florida, United States, 33617
- Clinical Pharmacology Services
-
Weston, Florida, United States, 33331
- Gold Coast Research
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Center for Prospective Outcome
-
Marietta, Georgia, United States, 30060
- Georgia Medical Research
-
-
Illinois
-
Chicago, Illinois, United States, 60616
- American Medical Research
-
Oak Brook, Illinois, United States, 60523
- American Medical Research
-
-
Indiana
-
Valparaiso, Indiana, United States, 46383
- American Medical Research
-
-
Iowa
-
Des Moines, Iowa, United States, 50265
- Iowa Pain Management Clinic, P
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- Mid America Physiatrists, PA
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- Best Clinical Trial, Inc.
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27401
- PharmQuest
-
-
Washington
-
Bellevue, Washington, United States, 98004
- Northwest Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients are included in the study if all of the following criteria are met:
- The patient is willing to provide written informed consent to participate in this study.
- The patient is 18 through 80 years of age.
- Women must be surgically sterile, 2 years postmenopausal, or, if of childbearing potential, using a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive [oral, transdermal, implanted, or injected contraceptives must be used in conjunction with a barrier method], or intrauterine device [IUD]) and agree to continued use of this method for the duration of this study.
- The patient has a diagnosis of chronic low back pain, resulting in functional disability of at least 3 months duration and is associated with any of the following: osteoarthritis, degenerative disc disease, or spondylolisthesis. Patients with other low back pain etiologies may qualify for the study with permission from the Cephalon medical monitor or designee.
- The patient is currently using 1 of the following: at least 60 mg/day or oral morphine/day, or at least 25 mcg transdermal fentanyl/hour, or at least 30 mcg oxycodone/day, as a stable dose of around-the-clock (ATC) therapy for at least the previous 7 days before enrollment into the study.
- The patient reports an average pain intensity score, over the prior 24 hours, of less than 7 (0=no pain through 10=worst pain) for their chronic low back pain.
- The patient experiences, on average, 1 to 4 BTP episodes (defined as temporary flares of severe or excruciating pain) per day while taking ATC opioid therapy, and on average, the duration of each BTP episode is less than 4 hours.
- The patient currently uses opioid therapy for alleviation of BTP episodes, occuring at the location of the chronic pain, and achieves at least partial relief.
- The patient is able to effectively self-administer the study drug.
Exclusion Criteria:
Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- The patient has uncontrolled or rapidly escalating pain as determined by the investigator (ie, the ATC therapy may be expected to change between the first and last treatments with study drug), or has pain uncontrolled by therapy that could adversely impact the safety of the patient or that could be compromised by treatment with study drug.
- The patient has known or suspected hypersensitivities, allergies, or other contraindications to any ingredient in the study drug.
- The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse.
- The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly increase the risk of treatment with potent synthetic opioids.
- The patient has medical psychiatric disease that, in the opinion of the investigator, would compromise collected data.
- The patient is expected to have surgery during the study and it is anticipated that the surgery will alleviate the patient's pain.
- The patient has had therapy before study drug treatment that, in the opinion of the investigator, could alter pain or response to pain medication.
- The patient is pregnant or lactating.
- The patient has participated in a previous study with ORAVESCENT fentanyl.
- The patient has participated in a study involving an investigational drug in the previous 30 days.
- The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
- The patient has any other medical condition or is receiving concomitant medication/therapy (eg, regional nerve block) that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise collected data.
- The patient is involved in active litigation in regard to their chronic pain.
- The patient has a positive urine drug screen (UDS) for a medication not prescribed by their physician or no reasonable explanation can be provided to the Cephalon medical monitor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
March 1, 2006
Study Registration Dates
First Submitted
September 14, 2005
First Submitted That Met QC Criteria
September 14, 2005
First Posted (Estimate)
September 22, 2005
Study Record Updates
Last Update Posted (Estimate)
May 9, 2014
Last Update Submitted That Met QC Criteria
May 8, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Back Pain
- Low Back Pain
- Breakthrough Pain
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Fentanyl
Other Study ID Numbers
- C25608/3042/BP/US
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Low Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Iran University of Medical SciencesNot yet recruitingLow Back Pain | Chronic Low-back Pain | Chronic Non-specific Low Back Pain | Cupping Therapy
-
Federal University of Minas GeraisRecruitingBack Pain | Low Back Pain | Chronic Low-back Pain | Back Pain Lower Back ChronicBrazil
-
Federal University of ParaíbaCompletedChronic Low Back Pain | Nonspecific Chronic Low Back Pain
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
University of Colorado, BoulderNational Institutes of Health (NIH); Radiological Society of North America; Psychophysiologic... and other collaboratorsCompletedChronic Pain | Back Pain Lower Back Chronic | Back Pain, LowUnited States
-
Spaulding Rehabilitation HospitalHighland Instruments, Inc.Active, not recruitingChronic Pain | Chronic Low Back PainUnited States
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)Active, not recruiting
-
Presidio Medical, IncRecruitingChronic Pain | Chronic Low-back PainAustralia
-
Dan RhonNational Center for Complementary and Integrative Health (NCCIH); 59th Medical... and other collaboratorsRecruitingLow Back Pain | Chronic Pain | Surgery | Back Pain Lower Back Chronic | Back Pain, LowUnited States
Clinical Trials on ORAVESCENT Fentanyl Citrate
-
CephalonCompletedPain | CancerUnited States
-
CephalonCompletedChronic Neuropathic PainUnited States
-
Samuel Lunenfeld Research Institute, Mount Sinai...Terminated
-
CephalonCompletedDiabetic Neuropathies | Osteoarthritis | Low Back Pain | MigraineUnited States
-
CephalonCompleted
-
Kyowa Kirin Co., Ltd.Completed
-
Nationwide Children's HospitalCompletedTetralogy of Fallot (TOF) | Ventricular Septal Defects (VSD) | Atrioventricular Septal Defects (AVSD)United States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
Beni-Suef UniversityUnknown